|
 |
|
|||||||
|
|||||||||
© 2002 by the American Diabetes Association, Inc.
Emerging Treatments and Technologies |
Increased Fructose Concentrations in Blood and Urine in Patients With Diabetes
1 Department of Internal Medicine, Teikyo University, School of Medicine, Tokyo, Japan
2 Department of Life Sciences (Chemistry), Graduate School of Arts and Sciences, the University of Tokyo, Tokyo, Japan
OBJECTIVE—To investigate fructose metabolic changes in patients with diabetes.
RESEARCH DESIGN AND METHODS—Serum and urinary fructose concentrations were determined in healthy subjects (n = 23) and in nondiabetic (n = 23) and diabetic patients (n = 26). Fructose was measured using our newly developed method, and 13C6-fructose was used as the internal standard. After adding sample to a fixed amount of internal standard, ion-exchange resins and high-performance liquid chromatography pretreatments were performed. Then, the amount of fructose in the sample was measured by gas chromatography-mass spectrometry.
RESULTS—Serum fructose concentrations in patients with diabetes (12.0 ± 3.8 µmol/l) were significantly higher than those in healthy subjects (8.1 ± 1.0 µmol/l, P < 0.001) and nondiabetic patients (7.7 ± 1.6 µmol/l, P < 0.001), and daily urinary fructose excretion was significantly greater in patients with diabetes (127.8 ± 106.7 µmol/day) than in nondiabetic patients (37.7 ± 23.0 µmol/day, P < 0.001). In patients with diabetes (n = 20), serum fructose concentrations (8.6 ± 1.8 µmol/l, P < 0.001) and daily urinary fructose excretion (63.4 ± 63.8 µmol/day, P < 0.01) significantly decreased by week 2 after admission.
CONCLUSIONS—The present results differed from those of previous studies in that we found that the serum and urinary fructose concentrations decreased rapidly, concomitant with an improvement in glycemia. Therefore, hyperglycemia was associated with increased serum and urinary fructose concentrations in patients with diabetes.
Abbreviations: 1,5-AG, 1,5-anhydroglucitol • ARI, aldose reductase inhibitor • FPG, fasting plasma glucose • GCMS, gas chromatography-mass spectrometry • HPLC, high-performance liquid chromatography • TG, triglyceride • UA, uric acid
CiteULike 
Del.icio.us 
Digg 
Reddit 
Technorati What's this?
This article has been cited by other articles:
|
|
 |
|
  V. Douard and R. P. Ferraris Regulation of the fructose transporter GLUT5 in health and disease Am J Physiol Endocrinol Metab, August 1, 2008; 295(2): E227 - E237. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Qiu, X. Wu, J. F. L. Chau, I. Y. Y. Szeto, W. Y. Tam, Z. Guo, S. K. Chung, P. J. Oates, S. S. M. Chung, and J. Y. Yang Aldose Reductase Regulates Hepatic Peroxisome Proliferator-activated Receptor {alpha} Phosphorylation and Activity to Impact Lipid Homeostasis J. Biol. Chem., June 20, 2008; 283(25): 17175 - 17183. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R J. Hine Time to get specific about dietary carbohydrates, affected populations, and diseases Am. J. Clinical Nutrition, April 1, 2008; 87(4): 1062 - 1062. [Full Text] [PDF]
|
|
|
|
 |
|
 M. Jozwik, M. Jozwik, C. Teng, and F. C. Battaglia Concentrations of monosaccharides and their amino and alcohol derivatives in human preovulatory follicular fluid Mol. Hum. Reprod., November 1, 2007; 13(11): 791 - 796. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. A. Stuart, M. E.A. Howell, and D. Yin Overexpression of GLUT5 in Diabetic Muscle Is Reversed by Pioglitazone Diabetes Care, April 1, 2007; 30(4): 925 - 931. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. A. Stuart, D. Yin, M. E. A. Howell, R. J. Dykes, J. J. Laffan, and A. A. Ferrando Hexose transporter mRNAs for GLUT4, GLUT5, and GLUT12 predominate in human muscle Am J Physiol Endocrinol Metab, November 1, 2006; 291(5): E1067 - E1073. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Diabetes | Diabetes Care | Clinical Diabetes | Diabetes Spectrum |